These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19603366)

  • 1. [Acute exacerbation of a chronic esophagitis].
    Winkler-Budenhofer UC; Ihrler S; Göke B; Kolligs FT
    Dtsch Med Wochenschr; 2009 Jul; 134(30):1517-9. PubMed ID: 19603366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Severe oesophagus injury as a complication during treatment with risedronic acid].
    Bijlsma A; Blokzijl H; Vecht J
    Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2105-7. PubMed ID: 18856023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risedronate-induced Hepatitis.
    Phillips MB
    Am J Med; 2007 Mar; 120(3):e1-2. PubMed ID: 17349419
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risedronate-induced arthritis.
    Yemisci OU; Yalbuzdag SA; Karatas M
    J Clin Rheumatol; 2010 Jun; 16(4):168-9. PubMed ID: 20414126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clindamycin-induced necrotising oesophagitis.
    Stanić Benić M; Karlović K; Čubranić A
    Postgrad Med J; 2016 Dec; 92(1094):741. PubMed ID: 27634634
    [No Abstract]   [Full Text] [Related]  

  • 7. Yearly zoledronic acid in postmenopausal osteoporosis.
    Karam R; Camm J; McClung M
    N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529
    [No Abstract]   [Full Text] [Related]  

  • 8. When do bisphosphonates make the most sense?
    Winzenberg T; Jones G
    J Fam Pract; 2011 Jan; 60(1):18-28. PubMed ID: 21209974
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
    J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
    J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
    Takada J; Iba K; Imoto K; Yamashita T
    J Bone Miner Metab; 2007; 25(2):142-6. PubMed ID: 17323185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.
    Yamaguchi K; Oizumi T; Funayama H; Kawamura H; Sugawara S; Endo Y
    J Oral Maxillofac Surg; 2010 Apr; 68(4):889-97. PubMed ID: 20056305
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
    Malden NJ; Pai AY
    Br Dent J; 2007 Jul; 203(2):93-7. PubMed ID: 17660780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of combination treatment for osteoporosis.
    Recker RR; Heaney RP
    J Clin Endocrinol Metab; 2001 May; 86(5):1888-9. PubMed ID: 11344178
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esophagitis dissecans superficialis associated with severe clindamycin toxicity.
    da Silva JR; Pinho R; Ponte A; Silva M; Furtado A; Carvalho J
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):363. PubMed ID: 25531990
    [No Abstract]   [Full Text] [Related]  

  • 19. Tolerability and compliance with risedronate in clinical practice.
    Hamilton B; McCoy K; Taggart H
    Osteoporos Int; 2003 May; 14(3):259-62. PubMed ID: 12730745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
    Gopal GK; Tam KL; Krishnan SP; Maddern IL
    N Z Med J; 2014 Feb; 127(1389):81-5. PubMed ID: 24548959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.